Resources

Worthwhile investments can be hard to recognise when discussing sustainability initiatives. Let's take a look at five with short payback periods.

​​​​​​​LinkGevity and Delta Biosciences, UAB, a Lithuanian pharmaceutical stability specialist, have been awarded funding from the UK Space Agency to prepare LinkGevity’s pioneering Anti-Necrotic therapeutic for deployment in space.

PIR International was delighted to partner with Slingshot Therapeutics on the appointment of Bobby Soni as Chief Business Officer.

Matt Evans and Liz Mercer are the duo behind ExpertLeader — a purpose-led joint venture dedicated to building leadership excellence in the UK life sciences sector. Their tailored programme is helping leaders grow with confidence, strengthen resilience, and make science work smarter for business success. In this member spotlight, they share more about their new venture and how they aim to create the life science leaders of the future.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.

In its latest annual review, the CGT Catapult demonstrates how it is uniquely positioned to deliver critical advances in the cell and gene therapy industry, from driving forward the industry’s productivity for the economy to improving patient outcomes.

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.

LinkGevity featured in Financial Times 5-part global series on Longevity companies. The article highlights how LinkGevity’s pioneering work on Anti-Necrotic technology is opening new frontiers in medicine, with potential for systemic healthspan regeneration.

A new paper published in the British Journal of Clinical Pharmacology sets out a roadmap for designing the next generation of system-level medicines - drugs that deliver the sweeping system-wide health benefits seen with GLP-1s such as Ozempic and Wegovy, but without their biological trade-offs and side effects.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced it has joined the American Heart Association Center for Health Technology & Innovation’s Innovators’ Network.

This blog explores the transformative BIA MAC Leadership Programme (LeaP) — a unique initiative empowering emerging bioprocessing professionals to accelerate their careers and strengthen leadership across the UK life sciences sector. With 76% of participants reporting career progression, LeaP is shaping the next generation of biotech leaders.

This blog explores the key investor insights, policy priorities, and technological breakthroughs shaping the future of UK TechBio, revealing how collaboration, talent, and data are driving the sector from innovation to global endurance.

Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion.

Research shows that while 85% of biopharma executives view partnerships as business-critical, around half report failure rates exceeding 60%. Baringa is on a mission to help life sciences organisations get partnering right.

Clinical trial results on drug free obesity treatment, published in peer reviewed journal, Obesity. Commercial launch in UK first, planned for 2027.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.